Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Purchased by Mackenzie Financial Corp

Mackenzie Financial Corp increased its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 46.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,328 shares of the company’s stock after purchasing an additional 7,678 shares during the quarter. Mackenzie Financial Corp’s holdings in Organogenesis were worth $68,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Assenagon Asset Management S.A. increased its position in shares of Organogenesis by 309.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 3,977,124 shares of the company’s stock worth $11,136,000 after purchasing an additional 3,005,450 shares during the last quarter. Acadian Asset Management LLC grew its position in Organogenesis by 18.6% in the 1st quarter. Acadian Asset Management LLC now owns 3,001,679 shares of the company’s stock valued at $8,521,000 after acquiring an additional 471,741 shares in the last quarter. GSA Capital Partners LLP grew its position in Organogenesis by 102.8% in the 1st quarter. GSA Capital Partners LLP now owns 531,218 shares of the company’s stock valued at $1,509,000 after acquiring an additional 269,315 shares in the last quarter. Los Angeles Capital Management LLC grew its position in Organogenesis by 45.9% in the 1st quarter. Los Angeles Capital Management LLC now owns 500,567 shares of the company’s stock valued at $1,422,000 after acquiring an additional 157,575 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new position in Organogenesis in the 1st quarter valued at about $100,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Lake Street Capital assumed coverage on Organogenesis in a research report on Friday, June 28th. They issued a “buy” rating and a $5.00 target price for the company.

Organogenesis Stock Performance

Shares of Organogenesis stock opened at $2.99 on Wednesday. Organogenesis Holdings Inc. has a one year low of $1.96 and a one year high of $4.70. The company has a market cap of $396.38 million, a PE ratio of 74.77 and a beta of 1.60. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.42 and a current ratio of 2.73. The business has a 50-day simple moving average of $2.76 and a 200-day simple moving average of $2.75.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. The company had revenue of $130.23 million for the quarter, compared to analyst estimates of $122.48 million. On average, equities research analysts forecast that Organogenesis Holdings Inc. will post -0.19 EPS for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.